1-6 of 6
Sattva Neelapu, M.D.
Close
Save search
Sort by
Journal Articles

A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.

Free
Nathan Fowler, M.D., Peter McLaughlin, M.D., Fredrick B. Hagemeister, M.D., Larry Kwak, M.D., Ph.D., Michelle Fanale, M.D., Sattva Neelapu, M.D., Luis Fayad, M.D., Barbara Pro, M.D., Crystal Sergent, RN, MSN, Shana R. S. White, B.S., Felipe Samaniego, M.D.
Journal: Blood
Blood (2009) 114 (22): 1714.
https://doi.org/10.1182/blood.V114.22.1714.1714
Published: 2009
Journal Articles

In Vitro and In Vivo Effects of CT-011, a Humanized Anti–PD-1 Monoclonal Antibody, in Combination with Rituximab against Human B-Cell Lymphomas.

Free
Fuliang Chu, PhD, Myriam Foglietta, MD, Hong Qin, MD, PhD, Rakesh Sharma, Ph.D., Qing Yi, MD, PhD, Galina Rodionov, Rinat Rotem-Yehudar, PhD, Sattva Neelapu, M.D.
Journal: Blood
Blood (2009) 114 (22): 724.
https://doi.org/10.1182/blood.V114.22.724.724
Published: 2009
Journal Articles

Analysis of Antigen-Specific T-Cell Responses and Regulatory T Cells Following Sibling Donor Immunization with Patient-Derived Idiotype Vaccine Prior to Non-Myeloablative Allogeneic Stem Cell Transplantation for Multiple Myeloma.

Free
Myriam Foglietta, MD, Sattva Neelapu, M.D., Daniel H. Fowler, Seth M. Steinberg, Larry W. Kwak, Michael R. Bishop
Journal: Blood
Blood (2009) 114 (22): 2250.
https://doi.org/10.1182/blood.V114.22.2250.2250
Published: 2009
Journal Articles

Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lyphoma without Prolonged Myelosuppression

Free
Felipe Samaniego, M.D., Michelle Fanale, M.D., Barbara Pro, M.D., F.B. Hagemeister, M.D., Peter McLaughlin, M.D., Jorge Romaguera, M.D., Sattva Neelapu, M.D., Maria Alma Rodriguez, M.D., Luis Fayad, M.D., Anas Younes, M.D., Larry W. Kwak, M.D., Ph.D
Journal: Blood
Blood (2008) 112 (11): 835.
https://doi.org/10.1182/blood.V112.11.835.835
Published: 2008
Journal Articles

Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups.

Free
Anas Younes, MD, Luis Y. Fayad, M.D., Andre Goy, M.D., Peter McLaughlin, M.D., Barbara Pro, M.D., Jorge Romaguera, M.D., Fredrick Hagemeister, M.D., Maria A. Rodriguez, M.D., Felipe Samaniego, M.D., Larry Kwak, M.D.Ph.D., Sattva Neelapu, M.D., L. Jeffrey Medeiros, M.D., Amanda Wedgwood, R.N., Michelle Fanale, M.D.
Journal: Blood
Blood (2006) 108 (11): 2742.
https://doi.org/10.1182/blood.V108.11.2742.2742
Published: 2006
Journal Articles

Six Weekly Doses of Rituximab Plus ABVD for Newly Diagnosed Patients with Advanced Stage Classical Hodgkin Lymphoma: Depletion of Reactive B-Cells from the Microenvironment by Rituximab.

Free
Anas Younes, MD, Peter McLaughlin, MD, Luis E. Fayad, MD, Andre Goy, MD, Jorge E. Romaguera, MD, Barbara Pro, MD, Maria A. Rodriguez, MD, Felipe Samaniego, MD, Larry Kwak, MD, PhD, Sattva Neelapu, M.D., Jeffrey Medeiros, MD
Journal: Blood
Blood (2005) 106 (11): 1499.
https://doi.org/10.1182/blood.V106.11.1499.1499
Published: 2005